Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Others would call it a tiny trial
Oh thank you!
So now it's anonymous wannabe? Earlier you claimed that ONCS IR was behind the PR.
which is it?
Volume so far is 210k, I would hardly call that market manipulation.
We all know how that looks like.
so again, you are the only one claiming this is orchestrated by ONCS
no facts to substantiate your claim
well you said ONCS IR department is behind it.
But yes maybe they did a freebee
but hey nice pop in the PPS, I am sure you share in are delight :)
I did, and it does not say 'paid by ONCS IR department'
please provide evidence to your claim that ONCS IR department is behind the SA article.
I held this one from 6,9 till 10 pps, got back in today at 7,5
Excellent opportunity!
Sorry to say but the killing only happens in your head unless you have given a sell order, then you killed your wallet. Stop worrying about these day to day share prices. The science is rocking and nothing negative had been released.
See this is an extra opportunity to add cheaply.
You do not know either that those institutional buyers will go in and out quickly, so please do not present this as a certain fact, it is not. At best speculation. It could be as realistic that they have bought in for medium or long term. Only time will tell.
Well regular readers of this forum will not recognize the 100% conversion rate.
We will be very fortunate if they can raise the 30% responder rate of Keytruda up to 70%
I am holding since .32 tpizza
Have been adding, and will again it goes to .75
Your link to milestone is rather useless Erik as Arch hasn't bothered to update it.
It still shows the 2013-14 milestones...
All I can see is the same couple op cheerleaders who are singing from the same hymne sheet.
Stock back down over 50%, lots of peaple in deep red
volume before price
but lets take it one step at a time and await the start of the human trial before we start speculating on market caps.
Thats impossible, nobody likes ONCS! At least those willing to admit it ;)
That is if the p2 results are good and to be confirmed in a p3
Lets not put the horse in front of the wagon ;)
Thanks for posting this Regis. Good information sources for newcommers.
I do believe Arch is flying stealth at the moment. We will have to be patient untill it gets discovered.
Well I am glad you miss her too.
Luckily Jordyn is still there. i am sure you appreciate that.
scandalous! probably Veronica's fault when she was forced out.
Or better, that poly-science no good of a CEO.
ah well the chief-med is nice :)
I would/t mind if they walk it down a little more, I will be ready to grab them.
Looking at how your "elsewhere" did the last 2 weeks, it seems that AVXL is the better pick, especially in the run up now to data on July 22nd.
All this says to me is that people still behave like a herd. So if you are smart you do not sell and wait 2 weeks to buy in. This seems to give better entry opportunities.
volume is drying up, float getting very small
any little sell orders influence the apps
keep your shares tightly locked away!
Also, witnessed before in many other bio stocks: a rally into the news, good results, and then a sell-off. So I would say lets keep it realistic.
Some weeks ago we had another couple of days with big volume but then nothing happened (except for the extra financing). I cannot find a reason for yesterdays big volume either.
Oh so you have inside information? Please share
Hi Ahab
I have traded in Arch last year but so far was holding off due weak financiald. That seems to solved now so looking to re-enter
This begs my question: as Juno is a market darling, what I am missing, 'cause I see so much more opportunities with a lot less adverse effects?
Is there something which I am not seeing but all the rest is? Why is the market then blind to Tap?
.75 yesterday was perfect
Inovio did this some months ago too, didn't do much for them
Thanks for sharing Wait
Multiplier is only 2
Cash raised was necessary, like a doctors medicine
Hopefully we can go full speed ahead
New cash raised
$3.0 Million in Net Proceeds Expected
FRAMINGHAM, MA -- (Marketwired) -- 07/01/15 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), is pleased to announce that it raised $3,066,000 in equity financing in a private placement to 19 accredited investors (the "Investors") on June 30, 2015 (the "Initial Closing"), and anticipates raising up to an additional $100,000 before concluding the private placement (the "2015 Private Placement Financing"). At the Initial Closing, the Company sold and the Investors purchased 13,936,367 Units at a purchase price of $0.22 per Unit. Each Unit consisted of a share of the Company's common stock, par value $0.001 per share ("Common Stock"), and a Series D Warrant to purchase a share of Common Stock at an exercise price of $0.25 per share at any time prior to the fifth anniversary of the issuance date of the Series D Warrant. Upon raising the final $100,000 in expected financing, a total of 14,390,913 Units will have been issued in connection with the 2015 Private Placement Financing, and the number of outstanding shares of Common Stock will increase from 78,081,487 to 92,472,400.
The 2015 Private Placement Financing is expected to provide at least $3.0 million of net proceeds to the Company, after expenses. Arch intends to use the proceeds from the 2015 Private Placement Financing to advance its hemostasis development program, predominantly by focusing on clinical trial expenses and further development of AC5™, and for general corporate purposes.
Dr. Terrence Norchi, President and CEO of Arch Therapeutics, Inc., said, "This is a pivotal year for Arch. We look forward to advancing our products in development, including starting and completing the first human trial with AC5. The proceeds from this transaction are an important contributor to our march toward product commercialization. We are grateful to our current and new investors for their support.
Thanks for taking the time to phone AVXL and report back here.
Excellent news!
Very good summary. Would have been excellent if somehow you slipped in his poly-science degree!
Tweeting is already such a thing of the past. I propose he snapchats.
Lol, too funny doc